Theravance Biopharma reports Q3 EPS 7c, consensus (5c)

Reports Q3 revenue $20.0M, consensus $19.89M. “Theravance delivered strong results in the third quarter, highlighted by record YUPELRI net sales and the achievement of non-GAAP breakeven, underscoring our commitment to financial and operational discipline,” said CEO Rick Winningham. “In parallel, we continue to advance ampreloxetine toward topline results from the pivotal Phase 3 CYPRESS study in Q1 of 2026. Backed by a strong balance sheet, durable YUPELRI cash flow, and multiple high-value milestones ahead, we approach this important catalyst from a position of strength-ready to deliver results that could transform the standard of care for multiple system atrophy patients and drive lasting value for patients and shareholders.”